Quantcast
Last updated on April 24, 2014 at 10:25 EDT

Cardiome Announces Changes to Senior Management Team

March 26, 2013

NASDAQ: CRME TSX: COM

VANCOUVER, March 26, 2013 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ:CRME)
(TSX:COM) today announces changes to the company’s senior management
team. William Hunter, M.D., previously interim Chief Executive Officer
and Director, has been appointed full time President and Chief
Executive Officer;  Karim Lalji has been promoted from Senior Vice
President of Commercial Affairs to Chief Commercial Officer; and Sheila
Grant has been hired as Chief Operating Officer.

“We are pleased with what Bill Hunter has accomplished in the last six
months including Cardiome’s restructuring and managing the return of
vernakalant from our previous partner, Merck & Co.,” said Bob Rieder,
Cardiome’s Chairman of the Board. “With Bill’s previous experience in
managing a successful commercial organization at Angiotech
Pharmaceuticals, we have every confidence in his leadership to move
Cardiome forward as a commercial stage entity.”

“Both Karim and Sheila have played pivotal roles in vernakalant’s
development and achievements to date,” said William Hunter, M.D.,
Cardiome’s President and CEO. “Karim’s experience in successfully
launching pharmaceutical products coupled with Sheila’s extensive
knowledge of vernakalant will be instrumental to the company’s future
success.”

Prior to Cardiome, Dr. Hunter co-founded Angiotech Pharmaceuticals in
1992 and assumed the position of Chief Executive Officer in 1997 when
Angiotech was a venture-stage, private, pre-clinical company with less
than 50 employees.  He led Angiotech through 3 rounds of private equity
financing, the initial public offering and listing on the Toronto Stock
Exchange and NASDAQ, over $1 billion in equity and debt financings, a
debt restructuring and 8 separate corporate acquisitions.  During that
time, Angiotech grew to become a profitable, diversified, healthcare
company with over 1,400 employees, several thousand commercially
available products, and 12 facilities in 5 countries. Dr. Hunter, a
physician by training, served as a practicing physician in British
Columbia for 5 years.

Mr. Karim Lalji has served as Cardiome’s SVP Commercial Affairs since
2007. As Chief Commercial Officer, he will be responsible for
overseeing the commercialisation of BRINAVESS(TM) in Europe and other
markets worldwide amongst other commercial and corporate business
development related activities. Prior to Cardiome, Mr. Lalji was
previously Vice President of Business Strategy and New Product
Commercialization at Sepracor, Inc. A key achievement at Sepracor, Inc.
was his leadership in the development and launch of Lunesta(®) (eszopiclone) for the treatment of insomnia. Mr. Lalji’s earlier
experience includes ten years with Merck & Company, where he led
several successful product launches including Crixivan(®) for HIV/AIDS and Fosamax(®) Once Weekly for osteoporosis. Mr. Lalji holds a Science Masters in
Health and Policy Management from Harvard University.

Ms. Sheila Grant was most recently Cardiome’s VP of Product Development,
with responsibility for the overall management of the vernakalant IV
and oral programs. She has overseen the development of vernakalant from
its initial pre-clinical studies through to commercialization. Ms.
Grant’s past roles at Cardiome have included Vice President, Commercial
Affairs and Director of Business & Clinical Development. Prior to
joining Cardiome, Ms. Grant acted as business consultant to De Novo
Enzyme Corporation and Coopers & Lybrand. Ms. Grant also worked in
research and development, production, and quality assurance with
Schering Agrochemicals U.K., Wellcome Biotechnologies U.K. and Serono
Diagnostics U.K. respectively. Ms. Grant holds an MBA degree from Simon
Fraser University.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one
marketed product, BRINAVESS(TM) (vernakalant IV), approved in Europe and other territories for the
rapid conversion of recent onset atrial fibrillation to sinus rhythm in
adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto
Stock Exchange (COM). For more information, please visit our web site
at www.cardiome.com.

Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
“believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,
“intend”, “expect” and similar expressions.  Forward- looking
statements may involve, but are not limited to, comments with respect
to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research and development and product and drug development. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others,
the following: general economic and business conditions in the United
States, Canada, Europe, and the other regions in which we operate;
market demand; technological changes that could impact our existing
products or our ability to develop and commercialize future products;
competition; existing governmental legislation and regulations and
changes in, or the failure to comply with, governmental legislation and
regulations; availability of financial reimbursement coverage from
governmental and third-party payers for products and related
treatments; adverse results or unexpected delays in pre-clinical and
clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products; decisions, and the
timing of decisions, made by health regulatory agencies regarding
approval of our technology and products; the requirement for
substantial funding to expand commercialization activities; and any
other factors that may affect our performance. In addition, our
business is subject to certain operating risks that may cause any
results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These
operating risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and
clinical development of our products; changes in our business strategy
or development plans; intellectual property matters, including the
unenforceability or loss of patent protection resulting from
third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture,
market and sell our products; the availability of capital to finance
our activities; and any other factors described in detail in our
filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to
place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary
statement. All forward-looking statements and information made herein
are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.


Source: PR Newswire